实用医学杂志 ›› 2021, Vol. 37 ›› Issue (22): 2871-2876.doi: 10.3969/j.issn.1006⁃5725.2021.22.009

• 临床研究 • 上一篇    下一篇

卵泡素样3基因与预后的关系在结肠癌组织中的表达及其与预后的关系

郭涛 辛振 王富豪   

  1. 淮北矿工总医院胃肠外科(安徽淮北 235000)
  • 出版日期:2021-11-25 发布日期:2021-11-25
  • 基金资助:
    安徽省重点研究和开发计划项目(编号:1804h08020267)

The expression of FSTL3 in colon cancer tissues and its association with prognosis

GUO Tao,XIN Zhen WANG Fuhao.   

  1. Department of Gastrointestinal Surgery,Huaibei Miners General Hospital,Huaibei 235000,China

  • Online:2021-11-25 Published:2021-11-25

摘要:

目的 探究卵泡素样3(FSTL3)基因在结肠癌中的表达及其对预后的影响。方法 通过TCGA 数据库检测FSTL3的表达与临床预后分析,免疫组化法检测FSTL3在结肠癌病例中的表达水平,并分析其表达与结肠癌临床病理学特征及预后之间的关系。选取SW620细胞为研究对象,分别构建FSTL3基因过表达和 沉默的细胞株,通过Western blot检测转染效率。MTT、克隆形成实验、Transwell 实验分别检测结肠癌细胞增殖和迁移能力的变化。结果 TCGA数据库中数据显示FSTL3表达明显上升,临床生存分析发现FSTL3高表 达患者的预后明显差于FSTL3低表达患者(P < 0.008)。应用ROC评估FSTL3对结肠癌的诊断效能较准确。 在临床病例中,FSTL3基因高表达(P < 0.001)。FSTL3在结肠癌中的表达与年龄(P = 0.049)、TNM 分期(P = 0.033)、浸润深度(P = 0.06)、远处转移(P = 0.001)有关,而与性别(P =0.386)、淋巴转移(P = 0.215)、分化程度 P = 0.565)无关。并且在结肠癌组织中,FSTL3高表达患者生存率显著低于低表达患者(P < 0.008)。MTT 验及克隆形成实验结果显示,在SW620细胞中,过表达FSTL3增强了细胞的增殖能力,敲低FSTL3则细胞增殖 能力降低(P < 0.05)。Transwell 实验表明过表达 FSTL3 使细胞迁移能力增强(P < 0.05),敲低 FSTL3 抑制了 SW620细胞的迁移能力(P < 0.05)。结论 FSTL3在结肠癌中高表达,与患者预后密切相关。沉默FSTL3 表达后抑制结肠癌细胞的增殖及迁移。FSTL3可能成为预测结肠癌患者发生发展及预后的分子标记物。

关键词:

结肠癌, FSTL3, 临床病理学特征, 增殖, 迁移

Abstract:

Objective To explore the expression of follicle⁃like 3(FSTL3)gene in colon cancer and its influence on the prognosis. Methods The expression of FSTL3 was detected and the clinical prognosis through the TCGA database was analyzed. The expression level of FSTL3 in colon cancer cases was detected by immuno⁃ histochemical analysis,and the relationship between its expression and the clinicopathological characteristics and prognosis was analyzed. SW620 cells were selected,cell lines with overexpression and silence of FSTL3 gene were constructed,respectively,and the transfection efficiency was detected by Western blot. MTT,clone formation test and Transwell test were used to detect changes in proliferation and migration capabilities. Results The expression of FSTL3 in the TCGA database was significantly increased,and clinical survival analysis showed the prognosis of patients with high FSTL3 expression was significantly worse than that of patients with low FSTL3 expression(P < 0.008). By using ROC,the evaluationof the diagnostic efficacy of FSTL3 for colon cancer was more accurate. In clinical cases,the FSTL3 gene was highly expressed(P < 0.001). The expression of FSTL3 in colon cancer was related to age(0.049),TNM stage(P = 0.033),depth of invasion(P = 0.06),distant metastasis(P = 0.001), and is related to gender(P = 0.386),lymphatic metastasis(P = 0.215),the degree of differentiation(P = 0.565 is irrelevant. And in colon cancer tissues,the survival rate of patients with high expression of FSTL3 was signifi⁃ cantly lower than that of patients with low expression(P < 0.008). MTT experiments and clone formation experi⁃ ments confirmed that in SW620 cells,overexpression of FSTL3 enhanced cell proliferation,while knocking down FSTL3 decreased cell proliferation (P < 0.05). Transwell experiments showed that overexpression of FSTL3 enhanced the migration ability of cells(P < 0.05),and knockdown of FSTL3 inhibited the migration ability of SW620 cells(P < 0.05). Conclusion FSTL3 is highly expressed in colon cancer and is closely related to the prognosis of patients. The expression of Shen FSTL3 inhibits the proliferation and migration of colon cancer cells. FSTL3 may be considered as a molecular marker for predicting the development and prognosis of colon cancer.

Key words:

colon cancer, FSTL3, clinicopathological characteristics, proliferation, migration